Signalling mechanisms underlying the myogenic response in human subcutaneous resistance arteries

Cardiovasc Res. 2001 Mar;49(4):828-37. doi: 10.1016/s0008-6363(00)00314-x.

Abstract

Objective: In this study we have examined for the first time the signal transduction mechanisms involved in the generation of pressure-dependent myogenic tone in human small resistance arteries from the subcutaneous vascular bed.

Methods: Myogenic responses and the subcellular mechanisms involved in the generation of this response were studied on a pressure myograph.

Results and conclusion: Human subcutaneous resistance arteries constricted 14.1+/-1.1% in response to an increases in intraluminal pressure from 40 to 80 mmHg and a further 3.5+/-1.7% in response to the 80-120-mmHg pressure step. Ca(2+) depletion or nifedipine abolished this response, whereas BAY K 8644 increased this response to 20.6+/-2.1% (P<0.05, response vs. control). The phospholipase C inhibitor U-73122 reduced the myogenic response to 2.5+/-1.0% at 80 mmHg (P<0.01, response vs. control) and abolished it at 120 mmHg. Diacylglycerol lipase inhibition with RHC-80267 abolished all myogenic responses to pressure. The protein kinase C (PKC) activator phorbol 12,13-dibutyrate increased the maximal myogenic response to 20.9+/-1.8% (P<0.05, response vs. control), whereas the PKC inhibitor calphostin C abolished myogenic responses. These data show that the generation of pressure-dependent myogenic tone in human subcutaneous arteries is dependent on Ca(2+) influx via voltage operated Ca(2+) channels (VOCCs) and a concomitant requirement for the activation of phospholipase C (PLC), diacylglycerol, and PKC.

MeSH terms

  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / pharmacology
  • Aged
  • Analysis of Variance
  • Arteries
  • Caffeine / pharmacology
  • Calcium / metabolism*
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels / drug effects
  • Calcium-Transporting ATPases / antagonists & inhibitors
  • Cyclohexanones / pharmacology
  • Enzyme Inhibitors
  • Estrenes / pharmacology
  • Female
  • Humans
  • In Vitro Techniques
  • Indoles / pharmacology
  • Lipoprotein Lipase / antagonists & inhibitors
  • Male
  • Middle Aged
  • Muscle, Smooth, Vascular / physiology*
  • Naphthalenes / pharmacology
  • Nifedipine / pharmacology
  • Phorbol 12,13-Dibutyrate / pharmacology
  • Protein Kinase C / antagonists & inhibitors
  • Pyrrolidinones / pharmacology
  • Ryanodine / pharmacology
  • Ryanodine Receptor Calcium Release Channel / drug effects
  • Signal Transduction / physiology*
  • Type C Phospholipases / antagonists & inhibitors
  • Vascular Resistance / physiology*

Substances

  • Calcium Channel Blockers
  • Calcium Channels
  • Cyclohexanones
  • Enzyme Inhibitors
  • Estrenes
  • Indoles
  • Naphthalenes
  • Pyrrolidinones
  • Ryanodine Receptor Calcium Release Channel
  • 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
  • Ryanodine
  • Phorbol 12,13-Dibutyrate
  • Caffeine
  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
  • 1,6-bis(cyclohexyloximinocarbonyl)hexane
  • Protein Kinase C
  • Lipoprotein Lipase
  • Type C Phospholipases
  • Calcium-Transporting ATPases
  • calphostin C
  • Nifedipine
  • Calcium
  • cyclopiazonic acid